ImmuneWatch SRL
1.0 FTEThe score of ImmuneWatch shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets -11 % Headcount (avg FTE) 0 %
Accounts of the company itself (not consolidated).
The full file covers 4 financial years; a free account shows 2. →ImmuneWatch's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 20 Jul 2026
- Year ended 31 Dec 2024filed on 11 Jul 2025
- Year ended 31 Dec 2023filed on 18 Jun 2024
- Year ended 31 Dec 2022filed on 21 Jun 2023
ImmuneWatch's financial analysis
- Solvency-17.4%sector median: 60.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of ImmuneWatch
ImmuneWatch's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0774.472.942
- VAT number
- BE0774472942
- Peppol
- Registered · 0208:0774472942 · as of 29 Oct 2026
- Legal form
- SRL
- Incorporated
- 23 Sep 2021
- Registered office
- 2000 Antwerp
- Size
- Micro · 1.0 FTE
- Latest accounts
- 2025 · filed on 20 Jul 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
ImmuneWatch (SRL) has been based in Antwerp since 2021, active in: research and experimental development on biotechnology. For 2025, it reports a net profit of 8,523 € and equity of −30,203 €; its revenue is not published. With 1.0 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at -17.4%, below the median of its sector (60.4%).
Companies similar to ImmuneWatch
Companies in the same business, of comparable size and area, outside its group.
- NanoBiotech Research and experimental development on natural sciences and engineering Diepenbeek · balance sheet 1,834 €
- Arquebus Solutions Europe Research and experimental development on natural sciences and engineering Machelen (Brab.) · balance sheet 186,058 €
- Nonaki Research and experimental development on natural sciences and engineering Nivelles · balance sheet 150,085 €
- TereLabs Research and experimental development on natural sciences and engineering Brussels · balance sheet 207,737 €
- STXC Research and experimental development on natural sciences and engineering Aalst · balance sheet 210,455 €
- GMPharm Research and experimental development on natural sciences and engineering Perwez · balance sheet 215,626 €
- Ceperitus Research and experimental development on natural sciences and engineering Ghent · balance sheet 217,514 €
- Jessav Research and experimental development on natural sciences and engineering Oosterzele · balance sheet 136,083 €
Frequently asked questions about ImmuneWatch
What is the revenue of ImmuneWatch?
ImmuneWatch files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of ImmuneWatch?
In Belgium, the VAT number is the company number prefixed with BE: BE0774472942 for ImmuneWatch, if the company is VAT-registered. Its company number (CBE) is 0774.472.942.
Where is the registered office of ImmuneWatch?
According to the CBE register, the registered office of ImmuneWatch is in 2000 Antwerp.
What is the equity of ImmuneWatch?
At the close of the 2025 financial year, the equity of ImmuneWatch amounts to -30,203 €, a solvency of -17.4% of total assets.
How many people work at ImmuneWatch?
1.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages ImmuneWatch?
The register lists 6 active mandates at ImmuneWatch. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of ImmuneWatch
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →